2023
Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsy
2018
The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI–ultrasound fusion‐targeted biopsy
Press B, Rosenkrantz AB, Huang R, Taneja SS. The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI–ultrasound fusion‐targeted biopsy. BJU International 2018, 123: 439-446. PMID: 30415476, DOI: 10.1111/bju.14615.Peer-Reviewed Original ResearchConceptsCancer detection rateMagnetic resonance imagingGleason scoreHypoechoic regionsInstitutional review board-approved databaseResonance imagingProstate-specific antigen densityFusion-targeted biopsyMultivariable regression analysisDetection rateProstate cancer detectionSignificant PCaUltrasonography findingsSingle surgeonSystematic biopsyProstate biopsySignificant cancerUnivariate analysisAntigen densityMRI suspicionSingle radiologistHigh riskUltrasound characteristicsRegion of interestBiopsyEvaluation and Treatment for Older Men with Elevated PSA
Press B, Bjurlin M, Taneja S. Evaluation and Treatment for Older Men with Elevated PSA. 2018, 21-41. DOI: 10.1007/978-3-319-78646-9_2.ChaptersElevated PSA levelsElevated PSAPSA levelsBenefits of biopsyProstate cancer mortalityRisk of mortalityBenefits of treatmentSubsequent cancer treatmentPredictive nomogramCancer mortalityElderly menProstate cancerSelection of menAge 76Older menClinical scenariosPatient healthGreater riskFurther evaluationCancer treatmentSelective biomarkersEarly detectionProstate MRIMenBiopsyDifferentiating Molecular Risk Assessments for Prostate Cancer.
Press B, Schulster M, Bjurlin MA. Differentiating Molecular Risk Assessments for Prostate Cancer. Reviews In Urology 2018, 20: 12-18. PMID: 29942196, PMCID: PMC6003298, DOI: 10.3909/riu0787.Peer-Reviewed Original Research